Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Moves Toward Biogenerics Goal With CoGenesys Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Israeli generics maker pays $400 million for the biopharma, which brings an advanced drug development platform called Albumin Fusion.
Advertisement

Related Content

HGS First Quarter Results Fair; Bigger News Ahead
HGS First Quarter Results Fair; Bigger News Ahead
HGS Cuts High Dose Albuferon In Phase III After Increased Pulmonary Events
HGS Cuts High Dose Albuferon In Phase III After Increased Pulmonary Events
Vegenics Licenses VEGF-C Development Rights From HGS Spinoff CoGenesys
Vegenics Licenses VEGF-C Development Rights From HGS Spinoff CoGenesys

Topics

Advertisement
UsernamePublicRestriction

Register

PS066768

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel